Articles Archives - QualityStocks

FridayJun 13, 2025 10:30 am

ONAR Holding Corp. (ONAR) Takes the Lead in AI-Driven Marketing as CEO Shares Vision

ONAR’s core focus is to accelerate revenue for middle-market companies via AI technology, innovation and digital excellence CEO notes that middle-market companies are in one of the most exciting yet demanding phases of growth ONAR follows a business model designed to be fast-moving, flexible and focused on delivering results, precisely what the middle-market sector needs ONAR Holding Corp. (OTCQB: ONAR) is staking its claim as a leader in AI-driven marketing, as CEO Claude Zdanow discusses the company’s powerful strategy to support middle-market firms through intelligent, data-focused innovation. In a recent Digital Journal interview, Zdanow detailed ONAR’s mission to deliver integrated,…

FridayJun 13, 2025 9:45 am

FAVO Capital Inc. (FAVO): Aligning for Growth in a Booming Alternative Lending Market

FAVO recently secured an $8 million equity investment to fund growth and accelerate its plan to uplist to the Nasdaq Capital Market The company voluntarily converted all super voting Series C Preferred Shares, simplifying its capital structure and improving governance transparency With SMBs turning away from traditional banks, FAVO’s revenue-based lending platform meets rising demand for fast, flexible funding solutions As inflationary pressures and elevated interest rates strain traditional financing channels, small and medium-sized businesses (“SMBs”) are increasingly seeking alternative funding sources to maintain liquidity and drive growth. Bank approval rates for SMB loans have dropped significantly - from 83%…

ThursdayJun 12, 2025 11:15 am

Brera Holdings PLC (NASDAQ: BREA) Applauds Portfolio Club Juve Stabia’s Strong Serie B Season, Serie A Run

Italian football club Juve Stabia finished 5th in Serie B and reached the semifinals of the Serie A promotion playoffs, recording the highest market value increase in Serie B since March 2025. Brera now holds a 38.46% stake in the club, with full FIGC approval for the acquisition. Attendance surged, with one match nearly selling out the 7,100-seat stadium, as Juve Stabia games have gained international attention, with broadcasts in the U.S., U.K., and Canada. A €5 million (US$5.85 million) subsidy was announced by the Campagna Region for Romeo Menti Stadium refurbishment. Brera Holdings (NASDAQ: BREA), an Ireland-based international holding…

ThursdayJun 12, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development

Financial momentum for Nutriband is indicated by its recent Q1 financial report Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report AVERSA(TM) Fentanyl has the potential to be the world's first abuse-deterrent opioid patch A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates. Financial momentum for Nutriband…

ThursdayJun 12, 2025 9:45 am

FAVO Capital Inc. (FAVO) Empowering Small, Mid-Sized Businesses in Critical Role of Private Credit Provider

The private credit market has experienced remarkable growth over the past decade, evolving from a niche segment to a cornerstone of the financial ecosystem FAVO Capital offers a range of financing options, including revenue-based funding and merchant cash advances The company’s impact is reflected in its impressive track record of supporting 10,000-plus small businesses, deploying more than $138 million in capital nationwide In today's increasingly fragile economic landscape, small and mid-sized businesses (“SMBs”) face mounting challenges in securing the funding necessary for growth and sustainability. Traditional banks, constrained by stringent regulations and risk-averse policies, often fall short in meeting the…

ThursdayJun 12, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is facing a severe ketamine shortage, prompting NRx to seek priority FDA review. NRX-100 eliminates benzethonium chloride, aligning with U.S. health initiatives to remove toxic preservatives. The company plans to petition the FDA to remove benzethonium chloride from all intravenous ketamine products. The filing complements the company’s NDA for NRX-100 for suicidal depression, with a PDUFA date expected in late 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a…

WednesdayJun 11, 2025 11:15 am

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) to Use Net Cash from Geddes Solar Power Project for Bitcoin Purchases

The company’s 3.79 MW Geddes facility is expected to begin generating revenue in June 2025. The initiative marks one of the first integrations of renewable energy and Bitcoin treasury management. Management will determine Bitcoin allocation based on market conditions and operational cash flow. The Geddes site, built on a closed landfill, reflects SolarBank’s dual focus on clean energy and land repurposing. This move could be extended to other solar and battery energy storage projects across the company’s 1+ GW pipeline. Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of…

WednesdayJun 11, 2025 10:30 am

Adageis Allows Healthcare Providers Maximum Value-Based Care Revenue with Simplicity and Visibility

The company offers a simple, AI-powered platform that helps providers identify their most valuable services, bringing clarity to complex insurance contracts, and highlighting where clinics can optimize revenue. The platform’s AI analytics help to identify high-risk patients and close care gaps efficiently, while letting providers track financial performance over time, aligning income with quality of care. Adageis continues to grow and expects to cover 580,000 patient lives by Q2 2025 and reach $100,000 in monthly recurring revenue. As healthcare shifts further toward value-based care, one challenge continues to frustrate providers: understanding how care quality translates into financial outcomes. Adageis, a…

WednesdayJun 11, 2025 9:45 am

Smart Hospitality: SkyTech Robots and the Future of U.S. Service Innovation Through AI

As the world watches Foxconn and NVIDIA deploy smart robotics in Taiwan’s cutting-edge hospitals, the same technology driven future is quietly taking shape across the American hospitality industry. Led by companies like SkyTech Automated Solutions, a wholly owned subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF). Foxconn's recent unveiling of its NVIDIA-powered hospital robots signals a monumental shift: combining real-time AI with robotics to improve labor efficiency, safety, and service personalization. The smart hospital model represents not just a technological leap, but a redefinition of how service delivery is imagined in labor-intensive environments. SkyTech is bringing that same revolution to the…

WednesdayJun 11, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline. The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL. Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations. Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways. With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support…

Site Search

Company Search

Category: Articles